Wrapping Up the Chicago Meeting (and So Much More!) | SWOG
Changing practice in Hodgkin lymphoma
Changing practice in Hodgkin lymphoma
Adding savolitinib to osimertinib produced clinically meaningful responses in EGFR-mutant, MET-overexpressed NSCLC following progression on osimertinib.
Welcome! You are invited to join a meeting: The Legacy of Giovana Thomas: Equitable Care and Outcomes in Otolaryngology. After registering, you will receive a…
In Ukraine, a country of around 44 million people, over 1.3 million individuals currently live with cancer. To access this subscriber-only content please log in…
NCI has launched a second-generation precision medicine clinical trial called Myeloid Malignancies Molecular Analysis for Therapy Choice, or myeloMATCH, a trial focused on acute myeloid…
In an industry that set its sights on reshaping cancer detection, GRAIL Inc. had the appearance of a pioneer. To access this subscriber-only content please…
As part of the IASLC’s ongoing series of podcasts in world languages, this episode brings together two leading lung cancer experts who discuss training and…
Juan Pablo Frias, M.D.; Jessica Hansen, MD
Take this survey powered by surveymonkey.com. Create your own surveys for free.
More research is needed to refine treatment strategies and identify predictive biomarkers for patient selection, according to researchers.
This study sought to assess predictors of financial toxicity in early-phase clinical trial participants.